Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

MAIA Biotechnology, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

POSTER DETAILS DURABILITY AND EFFICACY OF ATEGANOSINE (THIO) TREATMENT IN NON-SMALL CELL LUNG CANCER (NSCLC)

MAIA BIOTECHNOLOGY ABSTRACT SELECTED FOR POSTER PRESENTATION AT 2025 IASLC WORLD CONFERENCE ON LUNG CANCER

CHICAGO, AUG. 27, 2025 (GLOBE NEWSWIRE) -- MAIA BIOTECHNOLOGY, INC. (NYSE AMERICAN: MAIA) (MAIA, THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING TARGETED IMMUNOTHERAPIES FOR CANCER, TODAY ANNOUNCED THAT A MANUSCRIPT DETAILING DEVELOPMENTS IN ITS PHASE 2 THIO-101 CLINICAL TRIAL WAS ACCEPTED AND PUBLISHED IN THE INTERNATIONAL PEER-REVIEWED OPEN ACCESS SCIENTIFIC JOURNAL, CELLS, IN A SPECIAL ISSUE, CELLULAR MECHANISMS OF ANTI-CANCER THERAPIES

MAIA BIOTECHNOLOGY ANNOUNCES PUBLICATION OF INTERIM CLINICAL DATA ON TELOMERE TARGETING ANTICANCER AGENT IN PEER-REVIEWED JOURNAL CELLS

NEW YORK, AUG. 18, 2025 (GLOBE NEWSWIRE) -- DIAMOND EQUITY RESEARCH, A LEADING EQUITY RESEARCH FIRM WITH A FOCUS ON SMALL CAPITALIZATION PUBLIC COMPANIES HAS RELEASED AN UPDATE NOTE ON MAIA BIOTECHNOLOGY, INC. (NYSE: MAIA) FOLLOWING QUARTERLY RESULTS. THE UPDATE NOTE INCLUDES DETAILED INFORMATION ON THE MAIA BIOTECHNOLOGY'S BUSINESS, RECENT UPDATES, MANAGEMENT COMMENTARY, FINANCIAL RESULTS, VALUATION, AND RISKS.

DIAMOND EQUITY RESEARCH RELEASES UPDATE NOTE ON MAIA BIOTECHNOLOGY, INC. (NYSE: MAIA)

CHICAGO--(BUSINESS WIRE)--MAIA BIOTECHNOLOGY RECEIVES FDA'S FAST TRACK DESIGNATION FOR ATEGANOSINE AS A TREATMENT FOR NON-SMALL CELL LUNG CANCER.

MAIA BIOTECHNOLOGY RECEIVES FDA'S FAST TRACK DESIGNATION FOR ATEGANOSINE AS A TREATMENT FOR NON-SMALL CELL LUNG CANCER

CHICAGO--(BUSINESS WIRE)--MAIA BIOTECHNOLOGY ANNOUNCES PEER-REVIEWED JOURNAL PUBLICATION OF DATA VALIDATING SECOND GENERATION ATEGANOSINE PRODRUGS FOR ANTICANCER THERAPY.

MAIA BIOTECHNOLOGY ANNOUNCES PEER-REVIEWED JOURNAL PUBLICATION OF DATA VALIDATING SECOND GENERATION ATEGANOSINE PRODRUGS FOR ANTICANCER THERAPY

CHICAGO--(BUSINESS WIRE)--MAIA BIOTECHNOLOGY ANNOUNCES FIRST PATIENT DOSED IN EXPANSION OF PHASE 2 TRIAL FOR ATEGANOSINE IN ADVANCED NON-SMALL CELL LUNG CANCER.

MAIA BIOTECHNOLOGY ANNOUNCES FIRST PATIENT DOSED IN EXPANSION OF PHASE 2 TRIAL FOR ATEGANOSINE IN ADVANCED NON-SMALL CELL LUNG CANCER

CHICAGO--(BUSINESS WIRE)--MAIA BIOTECHNOLOGY WELCOMES LEADING HEPATOCELLULAR CARCINOMA CLINICIAN-SCIENTISTS TO SCIENTIFIC ADVISORY BOARD.

MAIA BIOTECHNOLOGY WELCOMES LEADING HEPATOCELLULAR CARCINOMA CLINICIAN-SCIENTISTS TO SCIENTIFIC ADVISORY BOARD

CHICAGO--(BUSINESS WIRE)--MAIA BIOTECHNOLOGY ANNOUNCES MASTER CLINICAL SUPPLY AGREEMENT WITH ROCHE FOR HARD-TO-TREAT CANCER THERAPIES.

MAIA BIOTECHNOLOGY ANNOUNCES MASTER CLINICAL SUPPLY AGREEMENT WITH ROCHE FOR HARD-TO-TREAT CANCER THERAPIES

CHICAGO--(BUSINESS WIRE)--MAIA BIOTECHNOLOGY TO PRESENT AT BIO INTERNATIONAL CONVENTION 2025.

MAIA BIOTECHNOLOGY TO PRESENT AT BIO INTERNATIONAL CONVENTION 2025

CHICAGO--(BUSINESS WIRE)--MAIA BIOTECHNOLOGY ANNOUNCES NEW RESPONDER IN NON-SMALL CELL LUNG CANCER PHASE 2 CLINICAL TRIAL.

MAIA Biotechnology, Inc.

MAIA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MAIA Biotechnology, Inc.

MAIA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MAIA